Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine LYB001 in Adults
NCT05552573Phase 1Unknown
- Sponsor
- Patronus Biotech
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19), sponsored by Patronus Biotech. Primary endpoint: The incidence of adverse reactions (ARs). Status: unknown.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05552573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552573.